ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer|BRCA1 Gene Mutation|brca2 Gene Mutation
Interventions: DRUG: ABT-888|DRUG: temozolomide
Sponsor: Steven J Isakoff, MD, PhD
Collaborators: Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Abbott